Acacia Pharma Raises $23.5 M Series B For Repurposing Drugs As Anti-Emetics
This article was originally published in The Pink Sheet Daily
Other product candidates in the cancer supportive care sector being developed by the U.K. virtual biotech include a liquid formulation of a muscarinic agonist for dry mouth and a megestrol/formoterol combination therapy for muscle wasting.
You may also be interested in...
EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.